- Investing.com
Cybin Inc., a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company’s development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds. The company has a strategic partnership agreement with Segal Trials to support PARADIGM, a multinational pivotal phase 3 program evaluating CYB003 for the adjunctive treatment of major depressive disorder. The company is headquartered in Toronto, Canada.
Metrics to compare | CYBN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCYBNPeersSector | |
---|---|---|---|---|
P/E Ratio | −2.2x | −3.9x | −0.5x | |
PEG Ratio | −0.05 | 0.01 | 0.00 | |
Price/Book | 1.0x | 1.2x | 2.6x | |
Price / LTM Sales | - | 0.7x | 3.2x | |
Upside (Analyst Target) | - | 0.0% | 41.2% | |
Fair Value Upside | Unlock | 6.6% | 6.2% | Unlock |